ClinicalTrials.gg
CompletedNCT00365612Updated Apr 10, 2008

Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

A Phase 4 interventional study of Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) in HIV Infections, sponsored by Gilead Sciences. Completed at 56 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-04-10.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies testing efavirenz in HIV Infections — none open to participants now, none under way, none of them phase 3. efavirenz · HIV Infections.

Planned enrollment
19th of 96
300 · median 75
Started
2006
with 9 others
Phase 4
28 of 101
none open now
Registered
61st of 101
by date
Lead sponsor
5 of 101
Gilead Sciences

Among the 101 studies testing efavirenz in HIV Infections, this one is the 19th largest by planned enrollment of the 96 interventional ones that give a count, is one of 10 that started in 2006, is one of 28 in phase 4, and was the 61st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 101 studies testing efavirenz in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About efavirenz

efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies testing efavirenz in HIV Infections as a file.
02

Study summary

To compare the effectiveness (efficacy, safety \& tolerability) of a Single Tablet Regimen of efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured by the proportion of patients who maintain viral load (HIV-1 RNA) \<200 copies/mL at Week 48.

03

Conditions studied

  • HIV Infections

Keywords

  • HIV
  • HIV-1
  • AIDS
  • Human Immunodeficiency Virus
  • HIV-1 Infection
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 positive patients who have maintained an HIV-1 viral load \<200 copies/mL, for at least 3 months.
  • Patients must be on their first HAART or have documented viral suppression on a PI-based regimen at the time of any prior change in therapy.
  • HAART must consist of either:

    1. A PI (with or without ritonavir) + at least 2 NRTIs or
    2. An NNRTI + at least 2 NRTIs.
  • Negative serum pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Patients who have taken any NNRTI prior to their current therapy.
  • Patients who have taken a NRTI-only therapy for greater than 7 days prior to their current therapy.
  • Patients who are currently taking EFV+FTC+TDF.
  • Patients who have a of \<60 mL/min by Cockcroft-Gault estimation.
  • Patients who have experienced virologic failure with any previous ARV therapy.
  • Patients who have documented resistance to any of the study agents at any time in the past.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Primary: Proportion of patients with HIV-1 RNA levels <200 copies/mL at Week 48

  2. Safety Outcome Measures: Adverse Events, Laboratory Tests

  3. Outcomes Research Measures: Quality of life, adherence, preference of medication, perceived ease of regimen, HIV symptoms

07

Study locations

56 sites
  • Hobson City, Alabama 36201, United States
  • Phoenix, Arizona 85006, United States
  • Beverly HIlls, California 90211, United States
  • Long Beach, California 90813, United States
  • Los Angeles, California 90069, United States
  • Oakland, California 94609, United States
  • San Diego, California 92103, United States
  • San Francisco, California 94114, United States
  • Tarzana, California 91356, United States
  • Denver, Colorado 80220, United States
  • Norwalk, Connecticut 06851, United States
  • Washington, District of Columbia 20037, United States
  • Ft. Lauderdale, Florida 33308, United States
  • Hollywood, Florida 33020, United States
  • Miami, Florida 33136, United States
  • Orlando, Florida 32803, United States
  • Pensacola, Florida 32504, United States
  • Port St Lucie, Florida 34952, United States
  • Safety Harbor, Florida 34695, United States
  • Tampa, Florida 33607, United States
  • Vero Beach, Florida 32960, United States
  • Atlanta, Georgia 30312, United States
  • Decatur, Georgia 30033, United States
  • Aurora, Illinois 60505, United States
  • Chicago, Illinois 60657, United States
  • Indianapolis, Indiana 46280, United States
  • Baltimore, Maryland 21201, United States
  • Boston, Massachusetts 02030, United States
  • Springfield, Massachusetts 01107, United States
  • Berkley, Michigan 48072, United States
  • Grosse Pointe Woods, Michigan 48236, United States
  • Minneapolis, Minnesota 55404, United States
  • St. Louis, Missouri 63139, United States
  • Hillsborough, New Jersey 08844, United States
  • Newark, New Jersey 07101, United States
  • Newark, New Jersey 07102, United States
  • Somers Point, New Jersey 08244, United States
  • Albany, New York 12208, United States
  • Brooklyn, New York 11203, United States
  • Mount Vernon, New York 10550, United States
  • New York, New York 10011, United States
  • Rochester, New York 14604, United States
  • Charlotte, North Carolina 28209, United States
  • Greenville, North Carolina 27858, United States
  • Winston-Salem, North Carolina 27157, United States
  • Akron, Ohio 44304, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Providence, Rhode Island 02906, United States
  • Dallas, Texas 75204, United States
  • Harlingen, Texas 78550, United States
  • Houston, Texas 77009, United States
  • Annandale, Virginia 22003, United States
  • Hampton, Virginia 23666, United States
  • Spokane, Washington 99204, United States
  • Ponce, 00731, Puerto Rico
  • San Juan, 00909, Puerto Rico
08

References and documents

Publications

  • Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF; AI266073 Study Group. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS. 2010 Feb;24(2):87-96. doi: 10.1089/apc.2009.0259. PubMed 20156091 ↗
  • Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf. PubMed 19357529 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Oct 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2006
First posted
Aug 17, 2006
Start
Jul 2006
Primary completionActual
Oct 2007
CompletionActual
Jan 2008
Last update
Apr 10, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00365612
Lead sponsor
Gilead Sciences
First posted
Aug 17, 2006
Start date
Jul 2006
Primary completion
Oct 2007
Completion
Jan 2008
Last update
Apr 10, 2008

Study contacts

John Flaherty
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efavirenz · Emtricitabine · Tenofovir

Start the discussion